AIM: The aim of the present study was to explore the effect of hepatic or renal dysfunction on the pharmacokinetics (PK), tolerability and safety of selexipag, an orally active prostacyclin receptor agonist. METHODS: Two prospective, open-label studies evaluated the PK of selexipag and its active metabolite ACT-333679 in healthy subjects and in subjects with mild, moderate and severe hepatic impairment or severe renal function impairment (SRFI). A single dose of 200 μg or 400 μg was administered. The PK parameters were derived from plasma concentration-time profiles. RESULTS: Exposure increased with the severity of hepatic impairment. Geometric mean ratios and 90% confidence intervals of the area under the concentration-time curve from time zero to infinity (AUC0-∞ ) for selexipag and ACT-333679 increased 2.1-fold (1.7-2.6) and 1.2-fold (0.9-1.6) in subjects with mild hepatic impairment, and 4.5-fold (3.4-5.8) and 2.2-fold (1.7-2.8) in subjects with moderate hepatic impairment when compared with healthy subjects. The two subjects with severe hepatic impairment showed similar dose-normalized exposure to that of subjects with moderate hepatic impairment. A 1.7-fold increase in the AUC0-∞ of selexipag and ACT-333679 was observed with SRFI compared with healthy subjects. Although exposure to selexipag and/or ACT-333679 was higher in subjects with mild or moderate hepatic impairment or SRFI vs. healthy subjects, no safety concerns were raised in these groups. CONCLUSIONS: Based on these observations, the PK data suggest that the clinically used starting dose needs no adjustments in patients with mild or moderate hepatic impairment or SRFI. However, doses should be up-titrated with caution in these patients. The small number of subjects limits the interpretation of selexipag PK in subjects with severe hepatic impairment.

CEPHA s r o Komenského 19 CZ 323 00 Pilsen Czech Republic

CRS Clinical Research Services Kiel GmbH 24105 Kiel Germany

Department of Clinical Pharmacology Actelion Pharmaceuticals Ltd Allschwil Switzerland

See more in PubMed

Galiè N, Negro L, Simonneau G. The use of combination therapy in pulmonary arterial hypertension: new developments. Eur Respir Rev 2009; 18: 148–53. PubMed

Hassoun PM, Mouthon L, Barbera JA, Eddahibi S, Flores SC, Grimminger F, et al. Inflammation, growth factors, and pulmonary vascular remodeling. J Am Coll Cardiol 2009; 54: S10–9. PubMed

Christman BW, McPherson CD, Newman JH, King GA, Bernard GR, Groves BM, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 1992; 327: 70–5. PubMed

Tuder RM, Marecki JC, Richter A, Fijalkowska I, Flores S. Pathology of pulmonary hypertension. Clin Chest Med 2007; 28: 23–42, VII. PubMed PMC

Chan SY, Loscalzo J. Pathogenic mechanisms of pulmonary arterial hypertension. J Mol Cell Cardiol 2008; 44: 14–30. PubMed PMC

Schannwell CM, Steiner S, Strauer BE. Diagnostics in pulmonary hypertension. J Physiol Pharmacol 2007; 58: 591–602. PubMed

Gomberg‐Maitland M, Olschewski H. Prostacyclin therapies for the treatment of pulmonary arterial hypertension. Eur Respir J 2008; 31: 891–901. PubMed

Kaufmann P, Niglis S, Bruderer S, Segrestaa J, Aanismaa P, Halabi A, et al. Effect of lopinavir/ritonavir on the pharmacokinetics of selexipag an oral prostacyclin receptor agonist and its active metabolite in healthy subjects. Br J Clin Pharmacol 2015; 80: 670–7. PubMed PMC

Kuwano K, Hashino A, Asaki T, Hamamoto T, Yamada T, Okubo K, et al. 2‐[4‐[(5,6‐diphenylpyrazin‐2‐yl)(isopropyl)amino]butoxy]‐N‐(methylsulfonyl)acetamide (NS‐304), an orally available and long‐acting prostacyclin receptor agonist prodrug. J Pharmacol Exp Ther 2007; 322: 1181–8. PubMed

Skoro‐Sajer N, Lang IM. Selexipag for the treatment of pulmonary arterial hypertension. Expert Opin Pharmacother 2014; 15: 429–36. PubMed

Baldoni D, Bruderer S, Muhsen N, Dingemanse J. Bioequivalence of different dose‐strength tablets of selexipag, a selective prostacyclin receptor agonist, in a multiple‐dose up‐titration study. Int J Clin Pharmacol Ther 2015; 53: 788–98. PubMed

Bruderer S, Hurst N, Kaufmann P, Dingemanse J. Multiple‐dose up‐titration study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of selexipag, an orally available selective prostacyclin receptor agonist, in healthy subjects. Pharmacology 2014; 94: 148–56. PubMed

Hoch M, Darpo B, Remenova T, Stoltz R, Zhou M, Kaufmann P, et al. A thorough QT study in the context of an uptitration regimen with selexipag, a selective oral prostacyclin receptor agonist. Drug Des Devel Ther 2015; 9: 175–85. PubMed PMC

Kaufmann P, Okubo K, Bruderer S, Mant T, Yamada T, Dingemanse J, et al. Pharmacokinetics and tolerability of the novel oral prostacyclin IP receptor agonist selexipag. Am J Cardiovasc Drugs 2015; 15: 195–203. PubMed PMC

Kaufmann P, Okubo K, Sidharta PN, Yamada T, Dingemanse J, Mukai H. Investigation of the absorption, metabolism, and excretion of 14C‐selexipag following oral administration to healthy male subjects. Clin Pharmacol Ther 2012; 91: Supplement S1, page S85.

Niglis S, Bruderer S, Okubo K, Mukai H, Dingemanse J. Investigation of potential pharmacodynamic and pharmacokinetic interactions between selexipag and warfarin in healthy male subjects. Clin Pharmacol Drug Dev 2013; 2: Supplement 1, page 3. PubMed

Yuan R, Venitz J. Effect of chronic renal failure on the disposition of highly hepatically metabolized drugs. Int J Clin Pharmacol Ther 2000; 38: 245–53. PubMed

Pugh RN, Murray‐Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646–9. PubMed

Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry: Pharmacokinetics in subjects with impaired hepatic function: study design, data analysis, and impact on dosing and labeling. May 2003. [online]. Available at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072123.pdf (last accessed 25 April 2016).

Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31–41. PubMed

Gault MH, Longerich LL, Harnett JD, Wesolowski C. Predicting glomerular function from adjusted serum creatinine. Nephron 1992; 62: 249–56. PubMed

Julious SA, Debarnot CA. Why are pharmacokinetic data summarized by arithmetic means? J Biopharm Stat 2000; 10: 55–71. PubMed

Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry: Pharmacokinetics in patients with impaired renal function — study design, data analysis, and impact on dosing and labeling. March 2010. [online]. Available at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM204959.pdf (last accessed 25 April 2016).

Clinicaltrials.gov. NCT01106014.: selexipag (ACT‐293987) in pulmonary arterial hypertension, GRIPHON Trial [online]. Available at https://clinicaltrials.gov/ct2/show/NCT01106014 (last accessed 25 April 2016).

McLaughlin VV, Channick R, Chin K, Frey A, Gaine S, Ghofrani A, et al. Effect of selexipag on morbidity/mortality in pulmonary arterial hypertension: results of the GRIPHON study. J Am Coll Cardiol 2015; 65: 10_S.

Sitbon O, Channick R, Chin KM, Frey A, Gaine S, Galiè N, et al. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med 2015; 373: 2522–33. PubMed

Flolan® 1.5 mg injection, Summary of Product Characteristics, 28 May 2014. GlaxoSmithKline Inc [online]. Available at https://www.gsksource.com/gskprm/htdocs/documents/FLOLAN.PDF (last accessed 18 November 2014).

Simonneau G, Torbicki A, Hoeper MM, Delcroix M, Karlocai K, Galie N, et al. Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. Eur Respir J 2012; 40: 874–80. PubMed

Dreisbach AW, Lertora JJ. The effect of chronic renal failure on hepatic drug metabolism and drug disposition. Semin Dial 2003; 16: 45–50. PubMed

Dreisbach AW, Lertora JJ. The effect of chronic renal failure on drug metabolism and transport. Expert Opin Drug Metab Toxicol 2008; 4: 1065–74. PubMed PMC

Gibson TP. Renal disease and drug metabolism: an overview. Am J Kidney Dis 1986; 8: 7–17. PubMed

McLean AJ, Morgan DJ. Clinical pharmacokinetics in patients with liver disease. Clin Pharmacokinet 1991; 21: 42–69. PubMed

Vanholder R, Van Landschoot N, De Smet R, Schoots A, Ringoir S. Drug protein binding in chronic renal failure: evaluation of nine drugs. Kidney Int 1988; 33: 996–1004. PubMed

Verbeeck RK. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol 2008; 64: 1147–61. PubMed

Benet LZ, Hoener BA. Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther 2002; 71: 115–21. PubMed

Heuberger J, Schmidt S, Derendorf H. When is protein binding important? J Pharm Sci 2013; 102: 3458–67. PubMed

Peterson L, Marbury T, Marier J, Laliberte K. An evaluation of the pharmacokinetics of treprostinil diolamine in subjects with hepatic impairment. J Clin Pharm Ther 2013; 38: 518–23. PubMed

Jenkins A, Wang‐Smith L, Marbury T, Laliberte K. Pharmacokinetics of treprostinil diolamine in subjects with end‐stage renal disease on or off dialysis. J Cardiovasc Pharmacol 2013; 61: 272–6. PubMed

Ventavis® (iloprost) inhalation solution, prescribing information, US package insert, Actelion Pharmaceuticals Ltd, Allschwil, Switzerland, March 2008. [online]. Available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021779s006lbl.pdf (last accessed 25 April 2016).